TPSF is a noncompetitive, potent inhibitor of estrogen receptor α, that does not compete with estrogen for binding to Erα. The compound has low toxicity and selectively targets E2-ERα-dependent cell growth. TPSF is effective in cells that become tamoxifen-resistant. It appears that down-regulation of ERα by TPSF is at list partially dependent to enhancement of proteasome-dependent degradation of ERα.
TPSF is a potent inhibitor of estrogen receptor α, that does not compete with estrogen for binding to Erα
Features and Benefits
This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
The Journal of biological chemistry, 283(19), 12819-12830 (2008-03-14)
Estrogen receptor alpha (ERalpha) plays an important role in several human cancers. Most current ERalpha antagonists bind in the receptor ligand binding pocket and compete for binding with estrogenic ligands. Instead of the traditional approach of targeting estrogen binding to
The Journal of biological chemistry, 285(53), 41863-41873 (2010-11-03)
The mechanisms responsible for 17β-estradiol (E(2))-stimulated breast cancer growth and development of resistance to tamoxifen and other estrogen receptor α (ERα) antagonists are not fully understood. We describe a new tool for dissecting ERα action in breast cancer, p-fluoro-4-(1,2,3,6,-tetrahydro-1,3-dimethyl-2-oxo-6-thionpurin-8-ylthio) (TPSF)
We offers many products related to Nuclear Receptors (Steroids) for your research needs.
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.